TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26840338
Drug: Flexible and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible and Fixed dosing intervals
Study: 25070545
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (600 mg fixed-dose)
Study: 23658438
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg daily)
Study: 23658438
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Atorvastatin + Etidronate)
Study: 18387406
Drug: Multivitamin/mineral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/mineral formulation
Study: 16608514
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplementation (25 g soy protein containing 60 mg isoflavones)
Study: 7499737
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms sulprostone in 250 saline solution infused at a rate of 100 micrograms/h 12 hours before the abortion
Study: 24200700
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 5 mg with sufentanil 2.5 μg followed by epidural 2% lidocaine 5 mL (Group L)
Study: 24200700
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 10 mg with sufentanil 2.5 μg followed by epidural saline 5 mL (Group C)
Study: 11422013
Drug: oral ARTS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral ARTS (150 mg)
Study: 11422013
Drug: oral DHA
Normalized name: Atabex DHA Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral DHA (120 mg)
Study: 8549572
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Study: 8549572
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer solution (330 ml with 150 mg sodium 1-[13C] acetate)
Study: 8549572
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Study: 2356344
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (15 ml)
Study: 2356344
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (20 ml)
Study: 2356344
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% (25 ml)
Study: 2356344
Drug: Bupivacaine 0.75%
Normalized name: BUPivacaine 0.75% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.75% (15 ml)
Study: 2356344
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (15 ml)
Study: 30172900
Drug: Lettuce seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lettuce seed (1000 mg daily for two weeks)
Study: 20356440
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection (treatment group)
Study: 18793398
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy for depression prior to standard weight loss treatment
Study: 18793398
Drug: Standard weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight loss treatment alone
Study: 16354802
Drug: Sitamaquine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 1.5 mg kg(‐1) day(‐1)
Study: 16354802
Drug: Sitamaquine 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 1.75 mg kg(‐1) day(‐1)
Study: 16354802
Drug: Sitamaquine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 2.0 mg kg(‐1) day(‐1)
Study: 16354802
Drug: Sitamaquine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitamaquine 2.5 mg kg(‐1) day(‐1)
Study: 14668277
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lysine/kg/d
Study: 14668277
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg lysine/kg/d
Study: 1521727
Drug: Simvastatin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10-20 mg/day) for 12 weeks
Study: 1521727
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment (baseline vs 12 weeks)
Study: 1521727
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (baseline vs 12 weeks)
Study: 30916916
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT) and motor imagery (MI)
Study: 30916916
Drug: Traditional rehabilitation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional rehabilitation (mime-therapy and myofascial-approach)
Study: 29220110
Drug: Transdermal opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal opioids
Study: 29220110
Drug: Polypharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacological therapy
Study: 29220110
Drug: Antidiabetic drugs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic drugs, antibiotics, previous weak opioid therapy
Study: 29220110
Drug: Anticoagulant, antidiabetic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant, antidiabetic, and central nervous system drugs
Study: 27327862
Drug: Abciximab followed
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab followed by a 12-hour infusion
Study: 24710131
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg/day in addition to disease-modifying antirheumatic drugs (DMARDs)
Study: 24710131
Drug: DMARD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD therapy alone
Study: 8852387
Drug: Hydroxyurea 500
Normalized name: hydroxyurea 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea 500 mg twice daily
Study: 8852387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyurea 500 mg twice daily and azidothymidine (AZT) 250 mg twice daily
Study: 8852387
Drug: Azidothymidine (AZT)
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azidothymidine (AZT) 250 mg twice daily
Study: 1352931
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Study: 1352931
Drug: Pancuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Study: 6371226
Drug: subject-alone relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subject-alone relaxation therapy
Study: 6371226
Drug: couples-relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: couples-relaxation therapy
Study: 6371226
Drug: couples-cognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: couples-cognitive therapy
Study: 27592690
Drug: Intermittent adductor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent adductor canal block (ACB) with 15 ml of 0.5% ropivacaine every 6 hours
Study: 27592690
Drug: Continuous adductor
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous adductor canal block (ACB) with 0.5% ropivacaine infusing at 2.5 ml/h
Study: 25268806
Drug: β-glucan 1000
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-glucan 1000 mg once daily for 7 days
Study: 22175661
Drug: Four-cluster solution
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-cluster solution
Study: 19858250
Drug: Azithromycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (2 g doses given 24 h apart)
Study: 19858250
Drug: Sulfadoxine-pyrimethamine (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (1,500 mg or 75 mg) or chloroquine (450 mg base daily for 3 days)
Study: 17991116
Drug: Intravaginal slingplasty
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal slingplasty (IVS) treatment
Study: 16390772
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of daily genistein
Study: 12170527
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy for endometriosis
Study: 11237197
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil capsules containing 1.5-1.8 g DHA/d
Study: 11237197
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil capsules containing 97% soybean oil plus 3% fish oil
Study: 1509912
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution at 400 mOsm/kg (Group 1)
Study: 1509912
Drug: Mannitol solution
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solution plus allopurinol (Group 2)
Study: 6233188
Drug: Motretinide 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motretinide 0.1% vanishing cream
Study: 31351241
Drug: Parent-Child Interaction
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Child Interaction Therapy-informed behavioral treatment
Study: 23845200
Drug: TrP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrP therapy (manual pressure applied to taut bands and passive stretching)
Study: 23845200
Drug: Simulated TrP
Normalized name: Trp
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated TrP therapy (no additional pressure, longitudinal stroking but no additional stretching)
Study: 23845200
Drug: TrP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TrP therapy
Study: 23845200
Drug: Simulated TrP
Normalized name: Trp
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated TrP therapy
Study: 21933376
Drug: Intermittent screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent screening and treatment (IST) of malaria
Study: 16403592
Drug: Fructose supplementation
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose supplementation (7.5 g) tri‐daily after each main meal
Study: 16403592
Drug: Maltodextrin supplementation
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin supplementation (7.5 g) tri‐daily after each main meal
Study: 8242506
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine administered at 13 months
Study: 8242506
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine administered at 15 months
Study: 8242506
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine (both groups)
Study: 23363776
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule per day for 4 months)
Study: 20829329
Drug: T/FAC (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/FAC (weekly paclitaxel × 12 followed by FAC × 4)
Study: 11220522
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg once daily
Study: 8695089
Drug: Pressure support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure support (PS) titrated to produce a tidal volume (VT) of 8 ml/kg body weight
Study: 7949749
Drug: Cyclic oestrogen/progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oestrogen/progestogen therapy (group 1, n = 20)
Study: 7949749
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral calcium dose of 2 g (group 2, n = 17)
Study: 7949749
Drug: Intermittent cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclic etidronate therapy (group 3, n = 19)
Study: 7949749
Drug: ADFR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADFR treatment with triiodothyronine and etidronate (group 4, n = 18)
Study: 3358644
Drug: Alprazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (mean daily dose 5.7 mg)
Study: 3358644
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean daily dose 7.5 capsules)
Study: 30390894
Drug: Individualized nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized nutritional support (126 kJ/kg and 1.5-2.0 g protein/kg) during hospitalization
Study: 21124326
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus a calcium channel blocker (CCB)
Study: 21124326
Drug: Olmesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan plus a thiazide diuretic
Study: 15310999
Drug: Immediate endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate endocrine treatment (luteinizing hormone‐releasing hormone agonist and 1 month of antiandrogen treatment or surgical castration)
Study: 15310999
Drug: Delayed endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed endocrine treatment
Study: 8534760
Drug: Aerosol amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol amphotericin B inhalations (10 mg twice daily)
Study: 2143046
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg two or three times daily for 3 months
Study: 31232992
Drug: Extraoral approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Study: 31232992
Drug: Intraoral approach
Normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral approach for BTX‐A injection into the lateral pterygoid muscle (20 IU BTX‐A)
Study: 28363363
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 0.25 mg/kg/dose every 6 hours for 48 hours
Study: 23972540
Drug: Healing Touch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healing Touch (HT) and Body Talk Cortices (BTC) for 6 months, with weekly HT sessions and daily BTC technique.
Study: 2187585
Drug: Cyproheptadine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (8 mg orally three times a day)
Study: 7033008
Drug: Des-phe insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Des-phe insulin (regular and semilinte preparations)
Study: 7033008
Drug: Des-phe insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Des-phe insulin
Study: 7033008
Drug: Unmodified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unmodified insulin
Study: 27519620
Drug: High-dose level
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose level SA3Ag
Study: 17685844
Drug: ACIDFORM gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIDFORM gel with a diaphragm
Study: 16015060
Drug: Endovascular therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapies including protection and thromboaspiration devices, new atherectomy devices, and cryoplasty.
Study: 7783062
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg qid
Study: 2515524
Drug: Altretamine preparation
Normalized name: Altretamine
DrugBank: Altretamine (DB00488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Altretamine preparation 1
Study: 2515524
Drug: Altretamine preparation
Normalized name: Altretamine
DrugBank: Altretamine (DB00488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Altretamine preparation 2
Study: 2515524
Drug: Altretamine preparation
Normalized name: Altretamine
DrugBank: Altretamine (DB00488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Altretamine preparation 3 (control)
Study: 7253868
Drug: Post-blood trial
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-blood trial after 920 ml equivalent of whole blood
Study: 31811339
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel dressing
Study: 28658251
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug detected
Study: 28658251
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral drug detected
Study: 25296623
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus nicotine patch (21 mg every 24 hours)
Study: 20433806
Drug: Intradermal hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal hepatitis B vaccination after topical application of imiquimod (250 mg)
Study: 20433806
Drug: Intradermal hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal hepatitis B vaccination without imiquimod application (control group)
Study: 18760149
Drug: Intravenous BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous BCAA supplementation (n=22; 19.6g/d)
Study: 11910268
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ziprasidone
Study: 23307953
Drug: Oxygen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen treatment
Study: 2117190
Drug: No oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oxygen treatment
Study: 6679234
Drug: Terazosin hydrochloride
Normalized name: Terazosin Hydrochloride
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terazosin hydrochloride (long-term therapy)
Study: 6679234
Drug: Terazosin hydrochloride
Normalized name: Terazosin Hydrochloride
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terazosin hydrochloride (short-term therapy)
Study: 31150095
Drug: LB 133
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LB 133 mg
Study: 25127173
Drug: LY2951742 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2951742 (150 mg) subcutaneous injection every 2 weeks for 12 weeks
Study: 25127173
Drug: Placebo subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection every 2 weeks for 12 weeks
Study: 19203562
Drug: CET +
Normalized name: CET
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CET + PSE (10 mg cetirizine and 120 mg pseudoephedrine)
Study: 19203562
Drug: CET (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: CET (single treatment)
Study: 19203562
Drug: PSE (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSE (single treatment)
Study: 17680909
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) + pharmacotherapy
Study: 15169696
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day, with option to increase to 40 mg/day at week 4)
Study: 11433064
Drug: 30 microgram
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microgram of LD vaccine
Study: 9757887
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes plus oxytocin (2 IU injected plus 0.07 IU/min infused for 60 minutes)
Study: 9757887
Drug: Vasoactive intestinal
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive intestinal polypeptide (VIP) 4 pmol x kg(‐1) x min(‐1) in 50 mL of normal saline infused i.v. for 60 minutes
Study: 3287685
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with vincristine, prednisone, L‐asparaginase and rubidomycin (Group B)
Study: 3287685
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with vincristine, prednisone and L‐asparaginase (Group A)
Study: 8764356
Drug: Niravoline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niravoline (2 mg dose, single 30-min i.v. infusion)
Study: 30497695
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate loading (400 mL, 2 hours before surgery)
Study: 22730955
Drug: Optimized treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment-as-usual (O-TAU)
Study: 17556623
Drug: Parenteral aminosidine
Normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral aminosidine sulphate (AS) 14 mg/kg/d for 21 days
Study: 17556623
Drug: Intravenous meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous meglumine antimonate (MA) 20 mg/kg/d for 28 days